FDA approves NDA for generic extended-release Concerta
Impax Laboratories recently announced receipt of an AB therapeutic equivalent rating and final FDA approval for its abbreviated New Drug Application for a generic version of extended-release Concerta for ADHD. The approved New Drug Application (NDA) is for 18-mg, 27-mg, 36-mg and 54-mg extended-release tablets of generic Concerta (methylphenidate hydrochloride).
Other Articles in this Edition
Research Note: Irritability and ADHD medications
FDA approves NDA for generic extended-release Concerta
Exclusion from school can trigger long-term psychiatric illness
Adderall might improve your test scores – but so could a placebo
Is my teen with ADHD ready to drive?
Why Kids With Pets Are Better Off
Executive Functioning and ADHD: What Parents Should Know
Keith Conners, Psychologist Who Set Standard for Diagnosing A.D.H.D., Dies at 84